- Decision aligned with Novartis’ global strategy to ensure continued supply and access to innovative medicines
- International Investment II Limited to take over ownership of Novartis business in Pakistan
- Manufacturing and distribution to continue under the same legal entity
- Agreement ensures job continuity for existing employees and retention of global healthcare expertise and skillsets in Pakistan
Karachi, May 8, 2025 – Novartis today announced that it has entered into an agreement with International Investment II Limited, an affiliated company of Muller & Phipps Pakistan (Private) Limited (“M&P”), to enhance access to innovative medicines in Pakistan.
Subject to the completion of necessary formalities, statutory and regulatory approval conditions, this agreement will ensure that Novartis manufacturing operations and the distribution of its products will continue in Pakistan under the same legal entity.
As part of the agreement, Novartis Pharma Pakistan Limited employees will be offered job continuity in their current roles with the provision of comparable compensation and benefit packages. This aims to ensure the retention of global healthcare expertise and skillsets that will benefit the growing innovative health ecosystem in Pakistan.
The announcement was made during a signing ceremony between Kevin Zou, Head of Asia Aspiring Markets at Novartis and Raymond Simkins, Group President and Christopher R. Boffey, Director for International Investment II Limited, as well as Kamran Nishat, Managing Director and CEO of M&P, in the presence of representatives from both companies.
"It is paramount to ensure continued supply and access to innovative medicines for the patients we serve and healthcare communities we partner with in Pakistan. This agreement also underscores the fair treatment of our employees and safeguards their livelihood. This shall remain a top priority as we support them through this transition,” said Kevin Zou, Head of Asia Aspiring Markets at Novartis.
In his comments, Raymond Simkins from International Investment II Limited and Kamran Nishat recognized the significant progress that Novartis had made in Pakistan since 1996 and expressed optimism for the next phase of promise and potential for all stakeholders involved.
About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.
Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.
###
Novartis Media Relations
E-mail: [email protected]